Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 6/20 | 0.35 |
| ▸ | CNR2 | P34972 | 6/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14986214 | 0.89 | LTA4H (0.40) | HDAC8CNR1CNR2 | |
| SCHEMBL2490558 | 0.88 | STING1 (0.36) | HDAC8CNR1CNR2STING1NR1H2 | |
| SCHEMBL18900144 | 0.88 | LTA4H (0.42) | HDAC8CYSLTR2CYSLTR1PDE3BPDE3A | |
| SCHEMBL530612 | 0.85 | LTA4H (0.40) | HDAC8CNR1CNR2STING1 | |
| SCHEMBL2491001 | 0.84 | PDE3B (0.47) | CNR1CNR2CYSLTR2CYSLTR1PDE3B | |
| SCHEMBL12210654 | 0.83 | HDAC8 (0.40) | HDAC8CNR1CNR2STING1PDE3B | |
| SCHEMBL530477 | 0.80 | PDE3B (0.30) | STING1PDE3BPDE3AP2RY12 | |
| SCHEMBL1742620 | 0.80 | CA12 (0.54) | — | |
| SCHEMBL1744467 | 0.79 | CA12 (0.55) | — | |
| SCHEMBL526413 | 0.78 | CA12 (0.53) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| US-8404678-B2 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| EP-2170890-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2011-10-26 | — | — | EP | disclosed |
| EP-2170890-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2011-10-26 | — | — | EP | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-2170890-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009016516-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016516-A2 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316656-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | TOMM34, TOMM70, TOMM40 | HDAC8 2231/4885CNR1 4550/4885CNR2 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.